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Abstract We investigated the biodistribution fol-
lowing the administration of nanosized (about 50 and
90 nm) cationic (f: ?30 and ?50 mV) micelles and
liposomes intended for drug delivery. The particles
were stable and well characterized with respect to size
and f potential. Ten 5- to 6-week-old male rats were
used. The animals were randomly allocated to five
groups receiving either cationic micelles or cationic
liposomes by single intravenous (IV) administration at
a dose of 100 mg/kg bodyweight by single intracer-
ebroventricular (ICV) injection at a dose of 50 lg or
no treatment. ICV administration was used to study
local distribution in the brain and IV administration to
study the systemic distribution of the particles. For
both types of particles, ICV administration showed
distribution in all ventricles in the brain while IV
delivery displayed distribution to the major organs
liver, spleen, kidney and lung, but not to the brain. Our
data suggest that cationic micelles and liposomes are
widely distributed in the body, indicating that these
could potentially be used as drug delivery carriers to
the major organs, but they do not cross the blood–brain
barrier to a significant extent, without a targeting
ligand attached. However, they are able to persist in
the ventricles of the brain up to 24 h after ICV
administration, demonstrating a new ability.
Keywords Micelles  Liposomes 
Distribution  Nanotechnology  Rhodamine B
Introduction
Nanoparticles (NPs) are promising candidates in drug
delivery systems due to their unique physio-chemical
properties, which enables them to target normally
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inaccessible areas and transport hydrophilic or lipo-
philic drugs or genes to these locations (Andresen
et al. 2005; Donaldson 2006; Kagan et al. 2005;
Kreuter and Gelperina 2008; Roney et al. 2005). There
has been great interest in using NPs to target specific
disease areas such as tumor tissue and areas affected
by neurodegenerative disorders in the central nervous
system (CNS) (Drummond et al. 1999; Re et al. 2012;
Schnyder and Huwyler 2005).
Drug delivery to the brain, to treat neurological and
psychiatric disorders, is complicated by the presence of
the blood–brain barrier (BBB) that selectively blocks
the passive transport of hydrophilic and charged
compounds (Lo et al. 2001). Several actions are being
taken in constructing particles which could penetrate
the BBB without disruption, thereby obtaining a
desired therapeutic effect in the brain tissue (Costan-
tino et al. 2005; Pardridge 2012; Tosi et al. 2007; Tosi
et al. 2008). Ideally, the particles should not contribute
to therapy or toxicity by themselves, but rather deliver
the therapeutic agent and subsequently be eliminated
by phagocytic cells. However, the control of such
delivery and the subsequent distribution of NPs in the
brain are at present poorly understood.
Not all NPs are potential candidates for drug
delivery. The NPs that show great potential as drug
carriers include lipid-like particles such as liposomes,
which are already used as drug delivery systems in
treatment of cancer (Andresen et al. 2010), but also
polymeric micelles are promising systems for different
drug delivery applications (Park et al. 2008). Knowl-
edge of biodistribution is an integral part of the
evaluation of new drug candidates to assess if the right
organs/tissues are targeted and to investigate potential
organ toxicity (Oberdorster et al. 2005). Distribution
can be altered by, e.g., binding of proteins in the blood
or cerebrospinal fluid (CSF), which can change the size
or other properties of the particles and thereby the
target tissue concentration (Moghimi and Hunter 2001;
Oberdorster et al. 2005; Owens and Peppas 2006).
The relationship between particle size and distri-
bution of gold particles has previously been evaluated.
Larger particles around 100 nm were distributed to
major organs such as liver, spleen and kidney, after IV
injection, whereas smaller particles around 50 nm
were also distributed to the lung and heart. Ten nm
particles were shown to be widespread in the tissues
after 24 h; here De Jong et al. (2008) detected gold
particles in all organs evaluated after IV injection
including the brain (de Jong et al. 2008). Silver NPs
with a size of 14 nm were after oral administration
found in major organs such as liver, kidneys, lung and
even found in brain (Loeschner et al. 2011).
PEGylation (coating with polyethylene glycol) of
particles has been known to prolong the circulation time
by shielding the particles from being cleared rapidly by
the reticular system (RES), but this coating has also been
reported to alter the biodistribution of the particles
(Moghimi and Szebeni 2003; Niidome et al. 2006;
Owens and Peppas 2006). Other factors than size and
coating influencing the distribution includes the surface
charge. For example, cationic effects have been sug-
gested to trap nanosized metal dendrimers in the kidneys
up to 4 days (Balogh et al. 2007). Cationic effects are,
e.g., desirable as an effective binding mechanism to
negatively charged DNA (Dai et al. 2011; Gjetting et al.
2011), but cationic effects have also shown to facilitate
cellular uptake (Thurston et al. 1998).
We recently reported toxicity of cationic NPs in the
hippocampus of the rat following intracerebroventric-
ular (ICV) administration (Knudsen et al. 2014). In the
present study, we have used NPs fluorescence labeled
with rhodamine B to investigate the systemic and CNS
distribution of cationic micelles and liposomes fol-
lowing IV or ICV injection, respectively, since to our
knowledge, there is limited information in the litera-
ture on the distribution of micelles and liposomes
in vivo, in particular to the brain.
Materials and methods
Nanoparticles
Preparation of rhodamine B-labeled cationic
liposomes
Lipids were purchased from Avanti Polar Lipids
(Alabaster, AL, USA). Cationic liposomes were
prepared from N-[1-(2,3-dioleyl)propyl]-N,N,N-trime-
thylammonium chloride (DOTAP, synthetic, 50 %
w/w) and cholesterol (plant source, 49.75 % w/w) and
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-
(lissamine rhodamine B sulfonyl) (ammonium salt,
DOPE-RhB, synthetic, 0.25 % W/W) at a concentra-
tion of 10 mg/ml in sterile phosphate-buffered saline
(PBS) as previously described (Gjetting et al. 2010).
Briefly, lipids were dissolved in chloroform and mixed
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in a glass vial. The solvent was evaporated under an
argon gas stream and the lipid film was dried in high-
vacuum overnight. Hydration was performed in the
PBS at 50 C for 2 h followed by sonication for 30 min
using a Bransonic water bath (MT-1510, 42 kHz,
80 W, setting ‘‘sonics’’, Branson Ultrasonics, Dan-
bury, CT, USA).
For characterization, 20 ll of cationic liposomes
were diluted in 1.8-ml buffer (5 % glucose containing
10 mM Na-HEPES, pH 7.4) in disposable cuvettes
(Sarstedt, Nu¨mbrecth, Germany) and the size distri-
bution of the NPs was measured by dynamic light
scattering (DLS) using a ZetaPALS (Zeta Potential
Analyzer) (Brookhaven Instruments, NY, USA) at
standard settings, typically 10 sub-runs of 30 s. Data
were fitted using the built-in software to estimate size
and polydispersity index (PDI). Subsequently, f
potential was measured with the same sample using
a conditioned electrode, typically by 10 runs, observ-
ing the relative residual from model fitting, p \ 0.04.
A typical preparation had an average size of
90 ± 1 nm (mean ± SEM) and a f potential of
?50 ± 2 mV. A polydispersity index of 0.1 was
measured for the sample, which indicated that the
cationic liposome preparation was highly monodis-
perse. CryoTEM images of DOTAP/cholesterol lipo-
somes have been published previously (Templeton
et al. 1997). A structured figure illustrates the
construction of the liposome in Fig. 1a.
Preparation of cationic micelles
The amphiphilic triblock-copolymer poly(methyl methac-
rylate)-b-poly(aminoethyl methacrylate)-b- poly(ethylene
N+
H Cl-
O
O
O
O
H
H
HH
H
HO
H -O
O
O
PO
SO3-
OO S
N+N O
NH
NH4+
O
O
O
O
a
DOTAP (50 %)
Cholesterol (49.75 %)
DOPE-RhB (0.25 %)
b
PMMA-b-PAEMA-b-PEG (99.75 %) PMMA-b-PAEMA(RhB)-b-PEG (0.25 %)
O
N
N
CO2H
NH
Cl
S
O O
O 12712
52O O
CH2CH2
OO
CH3
NH2
O O
O 12712
52O O
CH2CH2
OO
CH3
NH
+ RhB-ITC
+
Fig. 1 a Cationic
liposomes: chemical
structures and molar
composition: DOTAP
(50 %), cholesterol
(49.75 %) and DOPE-RhB
(0.25 %). b Cationic
micelles: structures and
reaction scheme of
synthesized triblock-
copolymer PMMA-b-
PAEMA-b-PEG with
fluorophore RhB-ITC—
approximately 0.25 % of
polymers are modified.
Upon hydration, both
materials self-organize into
fluorescent nanoparticles
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glycol) (PMMA-b-PAEMA-b-PEG) (500 mg, 40 lmol)
synthesized by our previously described method (Kumar
et al. 2012; Kumar et al. 2013), was dissolved in 14 ml of
dimethylformamide. To this clear polymer solution, 4 ml
of MilliQ water was added under stirring within a time
interval of 30 min followed by dropwise addition of
another 24 ml MilliQ water to facilitate homogenous
micelle formation. The cloudy micelle dispersion was
then transferred into a dialysis tube (MWCO = 12 kDa)
and dialysis was performed against MilliQ water for
2 days [size: 51 ± 2 nm, PDI 0.09, f potential:
32 ± 2 mV, as measured in glucose (5 %), Na-HEPES
(10 mM, pH 7.4)] and then against PBS buffer (pH 7.4)
for another 3 days. The final micelle concentration was
9.9 mg/ml (measured as dry mass after the dialysis
against water). The critical micelle concentration has
previously been determined to be\10 mg/l for this class
of triblock copolymer, and the structural properties of the
triblock copolymer have been evaluated by cryoTEM,
which showed the spherical morphology for the micelles
(Kumar et al. 2012).
Preparation of rhodamine B-labeled micelles
Ten milliliters of PMMA-b-PAEMA-b-PEG micelle
preparation (9.9 mg/ml) from above were dialyzed
against sodium carbonate buffer (50 mM, pH 9) for
2 days. The micelle dispersion was transferred into a
round bottom flask and rhodamine B isothiocyanate
[Sigma, 0.2 lmol from a 1 mg/ml stock solution in
dimethyl sulfoxide (DMSO)] was added and stirred at
room temperature for 12 h (Kumar et al. 2013). The
micelle preparation was transferred to a dialysis tube
with a molecular weight cut-off at 12 kDa and dialysis
was performed against the carbonate buffer for 3 days
to remove unreacted fluorophore. Subsequently, dial-
ysis against MilliQ water for another 3 days was
followed by quantification and characterization [size:
51 ± 2 nm, PDI: 0.09, f potential: 30 ± 2 mV,
measured in glucose (5 %), Na-HEPES (10 mM, pH
7.4)] and finally against PBS buffer (pH 7.4) for
another 3 days. The final micelle concentration was
9.8 mg/ml. The cationic micelles dispersed in the PBS
buffer were transferred into a sterile tube. The
coupling efficiency of the conjugation was estimated
to be 50 % resulting in a micelle preparation where
1/400 (0.25 %) of the monomeric triblock-copolymer
units in the micelle contains rhodamine B. A
structured figure illustrates the construction of the
micelle in Fig. 1b.
The stability of the particles was tested after storage
for 1 month without any change in size or f potential
(data not shown). The formulations were therefore
considered stable for at least the duration of the study.
Animals
Ten male Han Wistar rats (Crl:WI (Han)) were
obtained from Charles River (Wiga GmbH, Germany).
The rats were 4 weeks old at arrival and were housed
in humidity and temperature-controlled ventilated
cupboards (Scantainers, Scanbur technology, Karlsl-
unde, Denmark) with two rats per cage. They were
acclimatized for 2 weeks prior to examination and a
12-h day/night cycle was maintained. A standard
rodent diet (Altromin 1324, Brogaarden, Denmark)
and water were provided ad libitum. Following
acclimatization, the animals were randomly divided
into five groups (n = 2) receiving either cationic
micelles or cationic liposomes by single IV adminis-
tration at a dose of 100 mg/kg bodyweight, the same
particles by single ICV injection at a dose of 50 lg, or
no treatment. Body weights were recorded three times
(every second day) in the week before treatment and
on a daily basis during the study. Food consumption
was recorded per cage on a weekly basis. Cage-side
clinical observations were conducted several times
daily during the dosing period and changes were
recorded.
All experiments were conducted according to the
Danish Federal guidelines for use and care of labora-
tory animals and were approved by the Danish
Executive Order No. 1306 of 23 November 2007 on
Animal Testing.
Administration
The dosages were determined on preliminary studies
and were considered to be tolerable during short term
administration in rats. For the ICV administration,
animals were anesthetized with a 3:1 mixture of
HypNorm and Dormicum (Roche, Basel, Schweiz) at
a dose volume of 2.5 ml/kg bodyweight subcutane-
ously. Subsequently, using a stereotactic frame, a hole
was drilled in the skull on top of the right lateral
ventricle, at the following coordinates measured from
Bregma: anterior/posterior: -0.8 mm; medial/lateral:
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-1.4 mm; dorsal: -3.6 mm (Paxinos and Watson
2008). A 10-ll Hamilton syringe gauge 26S was
connected to the device and a volume of 5 ll of the NP
formulation (*10 mg/ml) was injected into the lateral
ventricle at a rate of 2 ll/min corresponding to a dose
of NPs of 50 lg. For the IV administration, the NPs
formulation (*10 mg/ml) was given once in a volume
of 10 ml/kg bodyweight corresponding to a NP dose of
100 mg/kg bodyweight. All particles were diluted in
PBS. Control animals were non-treated and functioned
as a control with respect to background fluorescence.
Sample collection
Twenty-four hours after injection, animals were
anesthetized with Avertin (Ampliqon, Odense, Den-
mark) using a dose of 10 ml/kg bodyweight intraper-
itoneally. Animals were sacrificed by exsanguination
while still anesthetized. Organs (liver, lung, spleen,
kidneys and brain) were isolated and examined
macroscopically.
Histology and biodistribution
Organs (brain, liver, lung, spleen and kidneys) were
frozen solid on crushed dry ice, to avoid crystallization
in the tissue, and then packaged in gold bags and stored
at -80 C. Frozen tissue was moved to a -20 C
freezer, 24 h before sectioning. Organs were embed-
ded in Tissue Tec (Sukura, AJ Alphen aan den Rijn,
The Netherlands) and sections were cut at 10 lm on a
Microtome (Leica Microsystems, Wetzlar, Germany).
The tissue sections were examined with a Nikon
Eclipse E1000 fluorescence microscope (Nikon Instru-
ments Europe B.V., Surrey, England) using Cyanine 3
(CY3) filter excitation wavelength 550 nm and emis-
sion at 570 nm. Microphotographs were taken with a
ProRes c14 Jenoptik camera (Jenoptik Optical Sys-
tems, Jena, Germany) using the image program
ImagePRO 6.2 (Media Cybernetics Inc., Bethesda,
MD, USA). The fluorescence was evaluated
qualitatively.
Results
Control animals were used to evaluate potential
background fluorescence to correct for this, when
analyzing the different treatment groups (Fig. 2). IV
administration was used to test systemic biodistribu-
tion of the NPs. Following IV administration, fluores-
cent particles could be detected in all animals 24 h
after administration in the collected organs.
In animals given rhodamine B-labeled micelles IV,
a high content of particles was observed in the liver
(Fig. 3a). The particles were distributed throughout
the liver and were located in portal areas and
interlobular tissue. The particles appeared to be
present in the vessels, as well as in the cytoplasm of
hepatocytes. In the spleen, the content appeared to be
as high as in the liver and the particles were primarily
located in the red pulp (Fig. 3b). In the lung tissue, the
micelles were located in high numbers in a few areas
(Fig. 3c). In the kidneys, a lower content of particles
was observed when compared to the liver and spleen.
The particles were mainly located in the glomeruli
(Fig. 3d). In general, the micelles were widely
distributed in compartments of the major organs after
IV administration (Fig. 3a–d).
In the brain, a few micelles were observed in the
choroid plexus of the lateral ventricle and in the
meninges (Fig. 3e, f). A few particles were also
located in the third ventricle and in the cortex of the
brain (Fig. 3g, h).
Following IV injection with rhodamine B-labeled
liposomes, a high number of particles were observed
throughout the liver (Fig. 4a). These particles
appeared to be located in the portal areas. In the
spleen, the content was similar to that found in the
liver, and the clusters of liposomes were located
primarily in the red pulp (Fig. 4b). In the lung,
particles were seen in a few smaller areas (Fig. 4c),
while the kidney showed particles located in the
glomeruli (Fig. 4d). In general, the liposomes were not
as widely distributed as the micelles after IV admin-
istration, the liposomes were more packed in clusters
(Fig. 4a–d) than observed with the micelles.
In the brain, the liposomes were detected in the
choroid plexus of the lateral ventricles (Fig. 4e). Parti-
cles were also found in the meninges (Fig. 4f, g). Finally,
a few particles were located in the cortex (Fig. 4h).
In animals injected ICV with micelles, a few particles
were detected in the liver and in the kidney (images not
shown). Particles may have been present in the spleen
and lung, but these were not positively identified during
microscopy. In the brain, a high content of micelles were
found in the ventricular system of the brain. They were
detected rostrally as well as caudally to the injection site
J Nanopart Res (2014) 16:2221 Page 5 of 11 2221
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and were located in both lateral ventricles, the third
ventricle, the cerebral aqueduct and in the fourth
ventricle in cerebellum (Fig. 5a, b).
After ICV administration of liposomes, a few
particle clusters were found in the lung tissue. In
addition, a few particles were observed in the portal
area of the liver, in the kidney and in the spleen (images
not shown). In the brain, a high content of liposomes
was observed in the ventricular system and distributed
in a similar manner as the micelles (Fig. 5c).
Fig. 2 Organ sections from non-treated control animals seen
through CY3 filter for fluorescence excitation at 550 nm;
emission 570 nm. The micrographs illustrate the background
fluorescence. Objectives 920. a Liver around the portal area,
b spleen, c lung, d kidney cortex with glomeruli, e the lateral
ventricle in the brain with choroid plexus and f brain meninges
Fig. 3 Organ sections obtained 24-h post IV administration of
rhodamine B-marked micelles seen through a CY3 filter for
fluorescence (excitation 550 nm; emission 570 nm). a–g Objec-
tives 920, h objective 940. a Liver, fluorescent particles in the
portal areas, b spleen, fluorescent particles in the red pulp,
c lung, area with clusters of fluorescent particles, d kidney,
fluorescent particles in the glomeruli, e Lateral ventricle in the
brain. Choroid plexus with a few fluorescent particles and
f brain, fluorescent particles in the meninges. g Few particles
located in the third ventricle of the brain. h Few particles located
in the cortex of the brain
2221 Page 6 of 11 J Nanopart Res (2014) 16:2221
123
The micelles and liposomes found in the brain
ventricles were located both at the choroid plexus and
along the walls of the brain ventricles (Fig. 5a–c).
Findings are summed up in Table 1.
Discussion
The present study was designed to mimic BBB
transport by injecting particles directly into the brain
by ICV, thereby surpassing the BBB and to compare
this with the biodistribution after IV administration.
Twenty-four hours after administration, the particles
were located in major organs after IV administration
and in the ventricles of the brain after ICV adminis-
tration. The protection by PEGylation offers the
particles a half-life up to 24 h (Moghimi et al. 2001).
The study duration of 24 h was chosen to balance the
ability of the particles to reach the target sites and their
half-life. Furthermore, the NP dose of 100 mg/kg
bodyweight should facilitate the micellar structures
that would not dissociate due to dilution given a
Fig. 4 Organ sections obtained 24-h post IV administration of
rhodamine B-marked liposomes seen through a CY3 filter for
fluorescence (excitation 550 nm; emission 570 nm). a, b, e, g,
h Objectives 920; c, d objective 910; f objective 940. a Liver,
portal area with clusters of fluorescent particles, b spleen,
clusters of fluorescent particles in the red pulp, c lung, small area
with cluster of fluorescent particles, d kidney, fluorescent
particles in the glomeruli, e lateral ventricle in the brain.
Choroid plexus with a few fluorescent particles. f Brain,
fluorescent particles in the meninges, g fluorescent particles
located in the leptomeningeal space between the lateral and the
third ventricle, and h single fluorescent particles located in the
cortex
Fig. 5 Brain sections obtained 24-h post ICV administration of
rhodamine B-marked micelles or liposomes seen through a CY3
filter for fluorescence (excitation 550 nm; emission 570 nm).
Objectives 910. a Lateral ventricles of the brain at the injection
site. Fluorescent micelles are located at the choroid plexus and
along the ventricle wall, b fourth brain ventricle with fluorescent
micelles along the ventricle wall and c lateral ventricles of the
brain at the injection site. Fluorescent liposomes are located
along the ventricle wall
J Nanopart Res (2014) 16:2221 Page 7 of 11 2221
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putative critical micelle concentration around 10 mg/l.
Rhodamine B applied as a fluorophore had been
successfully used in other studies testing the distribu-
tion of NPs (Harrison et al. 2012; Krasnici et al. 2003;
Vergoni et al. 2009). Toxicity of the NPs per se was
not assessed in this study as the fluorophore alone
could have an independent toxic effect (Avanti Polar
Lipids Inc. 2013). The fluorophore was built into the
lipid membranes of the NPs, therefore the RhB does
not drop off the NPs during the transport thereby
linking the observed fluorescent signals to the pre-
sence of the NPs themselves. The fluorescent NPs
were still visible 24 h after administration. This could
indicate that the particles are still circulating, but they
could potentially also be visible after being engulfed
by cells.
The development of safe drug delivery systems to
both CNS and systemic targets is a high priority in
modern drug development, but also the specific
delivery of agents to ensure an effective and long
lasting pharmacological effect. Biodistribution studies
are a way to determine target areas for potential drug
carriers and may also provide an information on organ
accumulation, clearance and safe use. Serum proteins
might alter the particle size, surface charge, and other
properties, that may change the particle distribution
and pharmacokinetics. Thus, cationic liposomes have
been shown to interact with anionic components in the
blood plasma thereby accelerating their clearance rate
and lowering their circulation time. In contrast,
PEGylation has been shown to minimize such protein
interactions and prolong the half-life of the NP species
(Zhao et al. 2011).
In this study, PEGylated micelles and non-PEGy-
lated liposomes were used. A similar distribution
pattern was observed 24 h post administration. Both
types of NPs were found in liver, lung, spleen, and
kidney and to a lesser degree in meninges in the brain
after the IV injections and primarily in the brain
ventricles after ICV injections. Compared to a study
by de Jong et al. (2008), who did not detect gold
particles at the size of 100 nm in lung tissue after IV
injection, we detected particles with a size around 90
and 50 nm in areas of the lung. Theoretically, non-
PEGylated liposomes should be cleared rapidly from
the blood after IV injection by elements of the RES
(Moghimi and Szebeni 2003). However, the relatively
high concentrations used may have increased their
half-life as some dose dependency has previously been
observed for similar NPs. Thus, Hong et al. (1999)
compared PEGylated and non-PEGylated liposomal
Doxorubicin and found that the half-life increased
from 12.5 h using a dose of 6 mg/kg up to 31.7 h when
a dose of 10 mg/kg bodyweight was used.
The cationic properties may increase cellular
uptake in general as seen by Zhao et al. (2011), who
found that cationic liposomes (85–140 nm) were
effectively taken up by rat aortic endothelial cells,
Table 1 Tissue distribution of particles
Tissue/no. of animals affected Control ICV cationic
micelle
IV cationic
micelle
ICV cationic
liposome
IV cationic
liposome
n = 2 n = 2 n = 2 n = 2 n = 2
Liver
Fluorescent particles located in portal veins or
interlobular connective tissue
0 2a 2 2a 2
Spleen
Fluorescent particles located primarily in the red pulp. 0 0 2 2a 2
Kidney
Fluorescent particles located in and around the
glomerulus
0 2a 2 2a 2
Lung
Fluorescent particles located in blood vessels 0 0 2 2a 2
Brain
Fluorescent particles located in all ventricles 0 2 2b 2 2b
a Few particle clusters observed
b Few particle clusters observed in meninges or ventricles
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possibly by endocytosis involving electrostatic inter-
actions between cells and liposomes (Zhao et al.
2011). A similar mechanism could explain the appar-
ent uptake by liver hepatocytes in the present study.
However, in contrast to our observations, Zhao et al.
found that cationic liposomes were preferentially
distributed to the lungs when compared with liver,
spleen and kidney following IV injections. This was
believed to be caused by the cationic surface, which
may interact with anionic substances in the serum, and
thereby causing the NPs to form aggregates, which
could accumulate in the lungs (Zhao et al. 2011). A
different distribution pattern was observed in the
present study where the distribution favored the liver
and spleen. However, Zhao et al. (2011) observed
better distribution, when particles were protected by
PEGylation, as observed with the PEGylated micelles
in the present study. Here, the PEGylation also
protected the particles from aggregation. The obser-
vations in the present study confirm that PEGylation
protects from aggregation compared to observations
with the liposomes, where clusters were more
observed compared with micelles. When the NPs start
to form aggregates, their size increase and this could
increase the clearance rate by uptake by RES, and
cleared to liver and spleen as observed (Lian and Ho
2001).
Balogh found that cationic gold particles (5 nm)
accumulate more in the kidney, while anionic accu-
mulate more in liver. They suggest that the cationic
surface charge decreases targeting to the liver (Balogh
et al. 2007). In this study, a more pronounced
accumulation was found in liver than in kidney with
cationic particles. It is not easy to compare different
particles, but this difference in accumulation could be
due to the time point investigated, when observing
clearance rate or difference in NP characteristics, such
as size, agglomeration of particles, or binding of
surface proteins (Hirn et al. 2011). The particles in the
present study were larger, and this could influence
their distribution, since smaller NPs may avoid
immune recognition (Balogh et al. 2007), thereby
having an altered distribution pattern.
In the current study, the NPs are transported via the
blood by systemic circulation to major organs such as
the liver and spleen, where the highest fluorescence
signals were observed. Here, the NPs may have been
trapped. For future studies, collection of feces and
urine as well as looking at other organs or tissues could
provide more detailed information about the distribu-
tion and degradation of these NPs.
Drug transport from blood to the CSF is regulated
by the choroid plexus, while transport from blood to
the brain interstitium is regulated by the BBB
(Pardridge 2011). In the rat, the CSF volume is around
90 ll (Pardridge 2011) and this volume is renewed
about 11 times daily (Johanson et al. 2008). We found
particles present in the brain ventricles 24 h after ICV
administration. This indicates that the particles may be
bound to structures in the ventricles, as they are not
cleared with the same rate as CSF. After IV injection,
we observed particles in the choroid plexus. The
choroid plexus is more easily penetrated than the
BBB, but it cannot be concluded that these empty
particles without a ligand attached crossed either the
choroid plexus or the BBB and entered the interstitial
fluid (Pardridge 2011). Sarin et al. (2008) has proposed
that particles larger than *12 nm are not able to
transverse the BBB (Sarin et al. 2008), which could
explain why noteworthy fluorescence in the brain was
not detected in the present study following IV
administration, and this indicates that the construct
would require a targeting ligand in future experiments,
if the size cannot be reduced. However, as micellar/
lipid structures are dynamic, deformable and may lose
their cargo during trafficking in the body, e.g., when
they are squeezing through cellular barriers, it cannot
be ruled out that the fluorescent tracer was lost during
crossing of the BBB, although the construct of the
tracer was designed not to come off the NPs as secured
by a lipid bond to RhB tracer.
A few particles were detected in liver after ICV
injection, which could indicate a clearance from the
brain ventricles. However, it may also be that particles
were mistakenly injected into blood vessel during the
administration.
In one of our recent studies, administration of
cationic particles was found to be associated with
toxicity in terms of cell death and inflammation in the
hippocampal area when injected ICV. However, no
toxicity was detected in other major organs examined
(liver, kidney, lung and spleen) after IV administration
(Knudsen et al. 2014). This study shows that the
cationic NPs are distributed well in major organ
systems and further supports that the NPs could
eventually be used for systemic drug delivery. Fur-
thermore, that there are correlation between the
persistence of the particles (at least for 24 h) and the
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toxicity in the brain observed in earlier investigations
(Knudsen et al. 2014). However, the present study
does not allow conclusions on potential tissue accu-
mulation over time and it should also be acknowl-
edged that different time points and doses may give
rise to different distribution patterns.
In conclusion, this study has shown a distribution of
RhB-labeled lipid NPs to major organs (liver, spleen,
kidneys and lung) after IV injection suggesting that
such particles could potentially be used as drug
delivery carriers to target these sites. The study has
also indicated that if particles are constructed to cross
BBB, lipid-based particles could persist in the ventri-
cles and potentially bind to specific elements in the
tissue or the CSF.
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